Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 193

Similar articles for PubMed (Select 23853602)

1.

Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines.

Tao P, Mahalingam M, Kirtley ML, van Lier CJ, Sha J, Yeager LA, Chopra AK, Rao VB.

PLoS Pathog. 2013;9(7):e1003495. doi: 10.1371/journal.ppat.1003495. Epub 2013 Jul 11.

2.

Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine.

Erova TE, Rosenzweig JA, Sha J, Suarez G, Sierra JC, Kirtley ML, van Lier CJ, Telepnev MV, Motin VL, Chopra AK.

Clin Vaccine Immunol. 2013 Feb;20(2):227-38. doi: 10.1128/CVI.00597-12. Epub 2012 Dec 12.

3.

Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles.

Sabhnani L, Manocha M, Sridevi K, Shashikiran D, Rayanade R, Rao DN.

FEMS Immunol Med Microbiol. 2003 Oct 15;38(3):215-29.

4.

Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid.

Boyer JL, Sofer-Podesta C, Ang J, Hackett NR, Chiuchiolo MJ, Senina S, Perlin D, Crystal RG.

Hum Gene Ther. 2010 Jul;21(7):891-901. doi: 10.1089/hum.2009.148.

5.

Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague.

Goodin JL, Nellis DF, Powell BS, Vyas VV, Enama JT, Wang LC, Clark PK, Giardina SL, Adamovicz JJ, Michiel DF.

Protein Expr Purif. 2007 May;53(1):63-79. Epub 2006 Dec 31.

6.

A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague.

Yamanaka H, Hoyt T, Yang X, Golden S, Bosio CM, Crist K, Becker T, Maddaloni M, Pascual DW.

Infect Immun. 2008 Oct;76(10):4564-73. doi: 10.1128/IAI.00581-08. Epub 2008 Aug 11.

7.

Expression of an immunogenic F1-V fusion protein in lettuce as a plant-based vaccine against plague.

Rosales-Mendoza S, Soria-Guerra RE, Moreno-Fierros L, Alpuche-Solís AG, Martínez-González L, Korban SS.

Planta. 2010 Jul;232(2):409-16. doi: 10.1007/s00425-010-1176-z. Epub 2010 May 12.

PMID:
20461403
8.

Cell-mediated immune response and Th/Th cytokine profile of B-T constructs of F1 and V antigen of Yersinia pestis.

Gupta G, Khan AA, Rao DN.

Scand J Immunol. 2010 Mar;71(3):186-98. doi: 10.1111/j.1365-3083.2009.02365.x.

PMID:
20415784
9.

Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague.

Powell BS, Andrews GP, Enama JT, Jendrek S, Bolt C, Worsham P, Pullen JK, Ribot W, Hines H, Smith L, Heath DG, Adamovicz JJ.

Biotechnol Prog. 2005 Sep-Oct;21(5):1490-510.

PMID:
16209555
10.

Purification and characterization of a recombinant Yersinia pestis V-F1 "Reversed" fusion protein for use as a new subunit vaccine against plague.

Goodin JL, Powell BS, Enama JT, Raab RW, McKown RL, Coffman GL, Andrews GP.

Protein Expr Purif. 2011 Mar;76(1):136-44. doi: 10.1016/j.pep.2010.10.011. Epub 2010 Nov 3.

PMID:
21055471
11.

Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague.

Leary SE, Griffin KF, Garmory HS, Williamson ED, Titball RW.

Microb Pathog. 1997 Sep;23(3):167-79.

PMID:
9281474
12.

Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis.

Anderson GW Jr, Leary SE, Williamson ED, Titball RW, Welkos SL, Worsham PL, Friedlander AM.

Infect Immun. 1996 Nov;64(11):4580-5.

13.

Targeting of LcrV virulence protein from Yersinia pestis to dendritic cells protects mice against pneumonic plague.

Do Y, Koh H, Park CG, Dudziak D, Seo P, Mehandru S, Choi JH, Cheong C, Park S, Perlin DS, Powell BS, Steinman RM.

Eur J Immunol. 2010 Oct;40(10):2791-6. doi: 10.1002/eji.201040511.

PMID:
20812236
14.

Protecting against plague: towards a next-generation vaccine.

Williamson ED, Oyston PC.

Clin Exp Immunol. 2013 Apr;172(1):1-8. doi: 10.1111/cei.12044. Review.

15.

Antigen engineering can play a critical role in the protective immunity elicited by Yersinia pestis DNA vaccines.

Wang S, Mboudjeka I, Goguen JD, Lu S.

Vaccine. 2010 Feb 23;28(8):2011-9. doi: 10.1016/j.vaccine.2009.10.059.

16.

Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague.

Williamson ED, Stagg AJ, Eley SM, Taylor R, Green M, Jones SM, Titball RW.

Vaccine. 2007 Jan 22;25(6):1142-8. Epub 2006 Oct 2.

PMID:
17101198
17.

Yersinia pestis YadC: a novel vaccine candidate against plague.

Murphy BS, Wulff CR, Garvy BA, Straley SC.

Adv Exp Med Biol. 2007;603:400-14.

PMID:
17966436
18.

Protective immunity in mice achieved with dry powder formulation and alternative delivery of plague F1-V vaccine.

Huang J, D'Souza AJ, Alarcon JB, Mikszta JA, Ford BM, Ferriter MS, Evans M, Stewart T, Amemiya K, Ulrich RG, Sullivan VJ.

Clin Vaccine Immunol. 2009 May;16(5):719-25. doi: 10.1128/CVI.00447-08. Epub 2009 Mar 4.

19.

Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice.

Brewoo JN, Powell TD, Stinchcomb DT, Osorio JE.

Vaccine. 2010 Aug 16;28(36):5891-9. doi: 10.1016/j.vaccine.2010.06.054. Epub 2010 Jul 12.

20.

Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts.

Arlen PA, Singleton M, Adamovicz JJ, Ding Y, Davoodi-Semiromi A, Daniell H.

Infect Immun. 2008 Aug;76(8):3640-50. doi: 10.1128/IAI.00050-08. Epub 2008 May 27.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk